NO333992B1 - Anvendelse av fumarsyreanhydrider og legemiddel omfattende et fumarsyreanhydrid - Google Patents
Anvendelse av fumarsyreanhydrider og legemiddel omfattende et fumarsyreanhydrid Download PDFInfo
- Publication number
- NO333992B1 NO333992B1 NO20031748A NO20031748A NO333992B1 NO 333992 B1 NO333992 B1 NO 333992B1 NO 20031748 A NO20031748 A NO 20031748A NO 20031748 A NO20031748 A NO 20031748A NO 333992 B1 NO333992 B1 NO 333992B1
- Authority
- NO
- Norway
- Prior art keywords
- radical
- fumaric acid
- use according
- cooh
- disease
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 34
- 229940079593 drug Drugs 0.000 title claims description 19
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical class O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 title description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 22
- 201000010099 disease Diseases 0.000 claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 14
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims abstract description 7
- FSQQTNAZHBEJLS-OWOJBTEDSA-N (e)-4-amino-4-oxobut-2-enoic acid Chemical class NC(=O)\C=C\C(O)=O FSQQTNAZHBEJLS-OWOJBTEDSA-N 0.000 claims abstract description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 6
- 239000001257 hydrogen Substances 0.000 claims abstract description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 4
- 102000003945 NF-kappa B Human genes 0.000 claims abstract description 4
- 108010057466 NF-kappa B Proteins 0.000 claims abstract description 4
- 230000001404 mediated effect Effects 0.000 claims abstract description 4
- 208000012268 mitochondrial disease Diseases 0.000 claims abstract description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 54
- -1 microtablets Substances 0.000 claims description 31
- 239000001530 fumaric acid Substances 0.000 claims description 25
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 25
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 9
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 9
- 210000004027 cell Anatomy 0.000 claims description 9
- 235000013477 citrulline Nutrition 0.000 claims description 9
- 229960002173 citrulline Drugs 0.000 claims description 9
- 239000008188 pellet Substances 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 8
- 208000006454 hepatitis Diseases 0.000 claims description 8
- FSQQTNAZHBEJLS-OWOJBTEDSA-M (e)-4-amino-4-oxobut-2-enoate Chemical compound NC(=O)\C=C\C([O-])=O FSQQTNAZHBEJLS-OWOJBTEDSA-M 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 231100000283 hepatitis Toxicity 0.000 claims description 6
- 239000006186 oral dosage form Substances 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 4
- 206010024648 Livedo reticularis Diseases 0.000 claims description 4
- 206010040070 Septic Shock Diseases 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 239000002702 enteric coating Substances 0.000 claims description 4
- 238000009505 enteric coating Methods 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 206010036030 Polyarthritis Diseases 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 208000030428 polyarticular arthritis Diseases 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 208000000103 Anorexia Nervosa Diseases 0.000 claims description 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 208000023514 Barrett esophagus Diseases 0.000 claims description 2
- 208000023665 Barrett oesophagus Diseases 0.000 claims description 2
- 208000023328 Basedow disease Diseases 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 206010014824 Endotoxic shock Diseases 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 201000005708 Granuloma Annulare Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 2
- 208000007514 Herpes zoster Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 2
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 claims description 2
- 208000002804 Osteochondritis Diseases 0.000 claims description 2
- 201000009859 Osteochondrosis Diseases 0.000 claims description 2
- 206010034010 Parkinsonism Diseases 0.000 claims description 2
- 208000031845 Pernicious anaemia Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 206010037391 Pulmonary granuloma Diseases 0.000 claims description 2
- 208000033464 Reiter syndrome Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 206010038923 Retinopathy Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- 206010044248 Toxic shock syndrome Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
- 206010003230 arteritis Diseases 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 206010061811 demyelinating polyneuropathy Diseases 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 201000002491 encephalomyelitis Diseases 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 229940126601 medicinal product Drugs 0.000 claims description 2
- 239000003094 microcapsule Substances 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 230000000750 progressive effect Effects 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 230000000637 radiosensitizating effect Effects 0.000 claims description 2
- 208000002574 reactive arthritis Diseases 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims 4
- 208000032839 leukemia Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010001257 Adenoviral conjunctivitis Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 208000005024 Castleman disease Diseases 0.000 claims 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 claims 1
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- 206010011830 Cytomegalovirus hepatitis Diseases 0.000 claims 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims 1
- 206010019663 Hepatic failure Diseases 0.000 claims 1
- 206010019799 Hepatitis viral Diseases 0.000 claims 1
- 206010023126 Jaundice Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 231100000354 acute hepatitis Toxicity 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 230000035622 drinking Effects 0.000 claims 1
- 206010014801 endophthalmitis Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 231100000835 liver failure Toxicity 0.000 claims 1
- 208000007903 liver failure Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000002088 nanocapsule Substances 0.000 claims 1
- 201000001369 pharyngoconjunctival fever Diseases 0.000 claims 1
- 201000001514 prostate carcinoma Diseases 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 201000001862 viral hepatitis Diseases 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 26
- 150000001413 amino acids Chemical class 0.000 abstract description 17
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 235000001014 amino acid Nutrition 0.000 description 15
- 150000003254 radicals Chemical class 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 239000012634 fragment Substances 0.000 description 8
- 229930182912 cyclosporin Natural products 0.000 description 7
- 239000003102 growth factor Substances 0.000 description 7
- 239000000813 peptide hormone Substances 0.000 description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 239000002858 neurotransmitter agent Substances 0.000 description 6
- 108010036941 Cyclosporins Proteins 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 4
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 239000003114 blood coagulation factor Substances 0.000 description 4
- 150000001470 diamides Chemical class 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 108010036949 Cyclosporine Proteins 0.000 description 3
- 108090000189 Neuropeptides Proteins 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 150000005690 diesters Chemical class 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 229940047120 colony stimulating factors Drugs 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182836 (R)-noradrenaline Natural products 0.000 description 1
- BSSNZUFKXJJCBG-OWOJBTEDSA-N (e)-but-2-enediamide Chemical class NC(=O)\C=C\C(N)=O BSSNZUFKXJJCBG-OWOJBTEDSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102400000113 Calcitonin Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 150000002237 fumaric acid derivatives Chemical class 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Chemical group 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- SFVVQRJOGUKCEG-OPQSFPLASA-N β-MSH Chemical compound C1C[C@@H](O)[C@H]2C(COC(=O)[C@@](O)([C@@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-OPQSFPLASA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
Abstract
Foreliggende oppfinnelse vedrører anvendelse av fumarsyreamider med den generelle formelen (I) hvori R1 representerer OR3 eller et D- eller L- aminosyre radikal -NH-CHR4-COOH bundet via en aminbinding, hvori R3 er hydrogen, et rettkjedet eller forgrenet, valgfritt substituert C1-24 alkylradikal, et fenylradikal eller C6-10 aralkylradikal og R4 er en sidekjede av en naturlig eller syntetisk aminosyre og R2 representerer et D- eller L- aminosyreradikal - NH-CHR5-COOH bundet via en amidbinding eller et peptidradikal omfattende 2 til 100 aminosyrer bundet via en aminbinding, hvori R5 er en sidekjede av en naturlig eller syntetisk aminosyre, for å fremstille et legemiddel for terapi av en autoimmun sykdom, for anvendelse i transplantasjonsmedisin, for terapi av mitokondriale sykdommer, samt for terapi av NF-kappaB medierte sykdommer.
Description
Foreliggende oppfinnelse vedrører anvendelse av fumarsyreanhydrider, vedrørende visse fumarsyre-mono- og diamider, eller monoamidofumarsyre-monoestere, hen-holdsvis, samt et legemiddel omfattende nevnte forbindelser.
I lang tid har fumarsyredialkylestere samt fumarsyremonoalkylestere og salter derav blitt vellykket anvendt for å behandle psoriasis. Anvendelsen er beskrevet i et antall patenter, for eksempel EP-A-0 188 749, DE-25 30 327, DE 26 21 214 eller EP-B-0 312 697.
Anvendelsen av fumarsyre mono- eller diestere er også beskrevet for behandlingen av autoimmune sykdommer slik som polyartritt, multippel sklerose (jf. DE 197 21 099.6 og DE 198 53 487.6), men også for anvendelse i transplantasjonsmedisin (jf. DE 198 53 487.6 og DE 198 39 566.3). Anvendelsen av fumarsyre mono- og diestere for behandlingen av NF-kappaB medierte sykdommer og behandlingen av mitokondriale sykdommer er også kjent fra de upubliserte tyske søknadene DE 101 01 307.8 og DE 100 00 577.2. Derimot beskriver alle de siterte dokumentene kun fumarsyre-mono- og diestere, valgfritt i formen av visse salter, dvs. forbindelser hvori en eller begge syrefunksjoner av fumarsyre er esterifisert med en alkohol.
På grunn av deres flyktighet og sublimabilitet derimot, har de ovennevnte fumarsyreestere ulempen av å være vanskelige å håndtere ved fremstilling av farmasøytis-ke produkter, spesielt de i fast form for oral administrasjon. Spesielt krever fremstillingen av slike produkter beskyttende tiltak slik som anvendelsen av pustemas-ker, hansker, beskyttende klær.
I tillegg absorberes fumarsyreesterne i det gastrointestinale system etter oral administrasjon og tas opp uspesifikt fra blodstrømmen av alle kroppscellene. Derfor er det nødvendig å administrere høye doser for å tilveiebringe et terapeutisk effektivt nivå av den aktive ingrediens på eller i målcellene.
Slike høye doser i sin tur fører til de kjent bieffektene av en fumarsyreterapi som rødmesymptomer (bli rød) eller gastrointestinal irritasjon (kvalme, diaré, luft). Selv om slike bieffekter kan reduseres betraktelig ved å administrere den aktive ingrediens i formen av mi krota bl ette r som beskrevet i den ovennevnte tidligere teknikk, kan de ikke unngås fullstendig.
Samtidig hydrolyseres fumarsyreesterne raskt i blodet og produktene av hydroly-sen, alkohol og fumarsyre eller fumarsyremonoester metaboliseres. For å beholde de terapeutiske effektive nivåer er gjentatt og hyppig administrasjon derfor nød-vendig. Selv om en viss tilpasning er observert når det gjelder bieffekter, ville en ytterligere reduksjon av bieffektene være ønskelig.
Derfor er det et formål med foreliggende oppfinnelse å tilveiebringe fumarsyrederi-vater som kan administreres strategisk, og er mer motstandsdyktige mot hydrolyse og lettere å håndtere, og anvendelsen av slike derivater.
Foreliggende formål oppnås ved anvendelse av fumarsyreanhydrider, vedrørende visse fumarsyre mono- og diamider eller monoamido fumarsyre-monoestere, hen-holdsvis, og et legemiddel for terapien av visse sykdommer og legemidler omfattende det samme.
Fumarsyre diamider og monoamider har også blitt beskrevet i US-A-5,242,905 og US-A-5,214,196 til Blank for behandlingen av psoriasis. Derimot beskriver disse siterte publikasjoner kun fremstillingen av enkle fumarsyre mono- eller diamider, men ikke fremstillingen av farmasøytiske produkter og anvendelsen av amidene på mennesker. En teoretisk fordel av fumaramidene over fumarsyreestere sitert av de ovennevnte publikasjoner er forbeholdet av visse aminosyrer fra fumaramidene i keratinocyter for å komplementere metabolske mangler i psoriasis.
Overraskende har oppfinnerne nå funnet at fumarsyre mono- og diamider eller monoamido fumarsyre-monoestere kan anvendes fordelaktig for terapien av en varia-sjon av sykdommer.
Spesielt vedrører det første aspektet av foreliggende oppfinnelse derfor anvendelsen av fumarsyreamider med den generelle formelen (I)
hvor
Ri representerer -OR3eller et D- eller L-aminosyreradikal -NH-CHR4-COOH bundet via en amidbinding, hvor R3er hydrogen, et rettkjedet eller forgrenet, valgfritt substituert Ci^alkylradikal, et fenylradikal eller C6.i0aralkylradikal, og
R2representerer et D- eller L-aminosyreradikal -NH-CHR5-COOH bundet via en amidbinding, hvor hver av R4og R5er uavhengig valgt fra gruppen bestående av sidekjedene av Ala, Val, Leu, Trp, Phe, Met, Tyr, Thr, Cys, Asn, Gin, Asp, Glu, Lys, Arg, His, Citrullin, Hcy, Hse, Hyp, Hyl, Orn, Sar og Me-Gly,
for å fremstille et legemiddel
(1) for terapi av en autoimmun sykdom valgt fra gruppen bestående av polyartritt, multippel sklerose, transplantat-mot-vert reaksjoner, barneinntrådt diabetes, Hashimotos thyroiditis, Graves sykdom, systemisk Lupus erythematodes, Sjøgrens syndrom, pernisiøs anemi og kronisk aktiv (= lupoid) hepatitt; (2) for terapi eller anvendelse i transplantasjonsmedisin; (3) for terapi av mitokondriale sykdommer fra gruppen bestående av Parkinson syndrom, Alzheimers sykdom, Chorea Huntington sykdom, retinopathia pigmentosa eller former av mitokondrial encefalomyopati; eller (4) for terapi av en NF-kappaB mediert sykdom valgt fra gruppen bestående av progressiv systemisk skleroderma, osteokondritis syphilitica (Wegeners sykdom), cutis marmorata (livedo reticularis), Behcet sykdom, panarteritis,
colitis ulcerosa, vasculitis, osteoarthritis, urinsyregikt, arteriosklerose, Reiters sykdom, pulmonar granulomatosis, typer av encephalitis, endotoksisk sjokk (septisk-toksisk sjokk), sepsis, pneumoni, encephalomyelitis, anorexia nevrosa, hepatitt, Rennert T-lymphomatosis, mesanginal nephritis, post-angioplastisk restenosis, re-perfusions-syndrom, cytomegaloviral retinopati, adenovirale sykdommer, AIDS, Guillain-Barré syndrom, post-herpetisk eller post-zoster neuralgia, inflammatorisk demyeliniserende polyneuropati, mononeuropathia multiplex, mucoviscidosis, Bech-terews sykdom, Barett oesophagus, EBV (Epstein-Barr virus) infeksjon, hjertere-modelering, interstitial cystitis, diabetes mellitus type II, menneskelig tumor radio-sensitisasjon, multi-resistens av ondartede celler for kjemoterapeutiske midler, granuloma annulare og kreft.
Foretrukne anvendelser av nevnte fumarsyreamider er angitt i uselvstendige krav 2-16.
Fumarsyreamider med formelen (I)refereres til:
hvori Ri representerer OR3eller et D- eller L-aminosyre radikal -NH-CHR4-COOH bundet via en aminbinding, hvori R3er hydrogen, et rettkjedet eller forgrenet, valgfritt substituert Ci-24alkylradikal, fortrinnsvis et Ci-6alkylradikal, et fenylradikal eller C6.i0aralkylradikal og R4er en sidekjede av en naturlig eller syntetisk aminosyre og
R2representerer et D- eller L-aminosyreradikal -NH-CHR5-COOH bundet via en amidbinding eller et peptidradikal omfattende 2 til 100 aminosyrer, fortrinnsvis 2 til 30 aminosyrer bundet via en amidbinding, hvori R5er en sidekjede av en naturlig eller syntetisk aminosyre,
med forbeholdet at
Når R3= H, er R2et peptidradikal valgt fra gruppen bestående av peptidhormoner, vekstfaktorer, cytosiner, neurotransmittere, nuropeptider, antistoff fragmenter, koaguleringsfaktorer og cyklosporiner samt derivater og fragmenter derav; og
Når Ri = -NH-CHR4-COOH, er R2et peptidradikal valgt fra gruppen bestående av peptidhormoner, vekstfaktorer, cutokiner, neurotransmittere, neuropeptider, antistoff- fragmenter, cyklosporiner og koaguleringsfaktorer samt derivater og fragmenter derav, eller representerer -NH-CHR5-COOH hvori R5er valgt fra gruppen bestående av sidekjedene av Ala, Val, Leu, Trp, Phe, Met, Tyr, Thr, Cys, Asn, Gin, Asp, Glu, Lys, Arg, His, Citrullin, Hcy, Hse, Hyp, Hyl, Orn, Sar og Me-Gly.
Betegnelsen "sidekjede av en naturlig eller syntetisk aminosyre" betyr radikalene av hver naturlige eller syntetiske aminosyre posisjonert på a-karbonatomet. Amino-syreradikalene Ri og R2kan være tilstede i D- og L-konfigurasjon, den naturlige L-konfigurasjoner er foretrukket. Under er de vanlige forkortelser og betegnelser i 3-bokstavkoden anvendt for å karakterisere aminosyrene.
Ifølge en utførelse representerer Ri -NH-CHR4-COOH og R2representerer -NH-CHR5-COOH hvori R4 og R5er uavhengig valgt fra gruppen bestående av sidekjedene av Ala, Val, Leu, Trp, Phe, Met, Tyr, Thr, Cys, Asn, Gin, Asp, Glu, Lys, Arg, His, Citrullin, Hcy, Hse, Hyp, Hyl, Orn, Sar og Me-Gly.
Ifølge en annen utførelse representerer Ri -OR3og R2representerer et L-aminosyre radikal -NH-CHR5-COOH hvori R5er valgt fra gruppen bestående av sidekjedene av Ala, Val, Leu, Trp, Phe, Met, Tyr, Thr, Cys, Asn, Gin, Asp, Glu, Lys, Arg, His, Citrullin, Hcy, Hse, Hyp, Hyl, Orn, Sar og Me-Gly.
Spesielt fordelaktig er R5en polar aminosyre i begge utførelser, enda mer foretrukket en ladningsbærende aminosyre valgt fra gruppen bestående av aspargin, glutamin, lysin, arginin og histidin.
Når radikalet Ri representerer -OR3, dvs. når forbindelsen av formelen (I) som skal anvendes er en monoamido fumarsyre monoester eller monoamid, er R3fortrinnsvis valgt fra gruppen bestående av et lineært, forgrenet, cyklisk, mettet eller umet-tet Ci-24alkylradikal, fortrinnsvis et C1-6alkylradikal, et fenylradikal eller en Ci-6aralkylradikal og dette radikalet er valgfritt substituert med halogen (F, Cl, Br, I), hydroksy, Ci-4alkoksy, nitro eller cyano. Fortrinnsvis er R3metyl, etyl, n-propyl, isopropyl, n-butyl, sec-butyl, t-butyl, pentyl, cyklopentyl, 2-etylheksyl, heksyl, cykloheksyl, heptyl, cykloheptyl, oktyl, vinyl, a Hyl, 2-hydroksyetyl, 2- eller 3-hydroksypropyl, 2,3-dihydroksypropyl, 2-metoksyetyl, metoksymetyl eller 2- eller 3- metoksypropyl. Mest foretrukket er R3metyl eller etyl.
Ifølge en annen utførelse representerer Ri -OR3, fortrinnsvis med R3= metyl eller etyl, og R2representerer et peptidradikal med 2 til 100, fortrinnsvis 2 til 30 amino og mest foretrukket 5 til 25 aminosyrer bundet via en aminbinding. Peptid radi ka le-ne kan være naturlige, rekombinante eller syntetiske peptid radi ka ler.
Mer foretrukket er peptid rad i ka let R2valgt fra gruppen bestående av peptidhormoner, vekstfaktorer, cytokiner, neurotransmittere, neuropeptider, antistoff fragmenter, koaguleringsfaktorer og cyklosporiner samt derivater og fragmenter derav. Nevnte peptider kan renses fra naturlige kilder, gjenvinnes ved rekombinante me-toder eller syntetiseres i henhold til kjente prosesser. Anvendelsen av syntetiske peptider er foretrukket.
Å koble fumarsyrelegemet til et slikt funksjonelt peptid har fordelen av at peptidet tilveiebringer en transmisjon av den aktive ingrediens "fumarsyrelegeme" til mål-celler med hvilket peptiddelen av amidene samvirker. Samtidig kan peptiddelen ha dens egen effekt på sykdommen som skal behandles slik at en kombinasjonsterapi utføres i dette tilfellet. Derimot tillater en kombinasjonsterapi og/eller strategisk administrasjon reduksjon av dosen som skal administreres i en ønskelig, og kanskje også synergistisk måte.
Ifølge en foretrukket utførelse kan peptidradikalet være et cyklosporinradikal hvis syklus har blitt kløvet ved hver peptidbinding for å gå inn i fumarsyreamidbindingen. Generelt kan alle cyklosporiner bindes til fumarsyreamidbindingen ved en amidbinding. Fordi cyklosporiner er cykliske peptider er peptidringen vanligvis kløvet ved enhver posisjon (ved enhver amidbinding) for å oppnå en lineærisert cyklosporin i stand til å gå inn i en amidbinding. Fortrinnsvis anvendes cyklosporin A lineærisert før posisjon 1.
Betegnelsen "peptidhormoner" som anvendt her betyr fysiologisk høyt aktive peptider med omtrent opp til 100 aminosyrer som utvikler en hormoneffekt eller hormonlignende effekt. Eksempler er de glandulære peptidhormonene av hypofysen slik som kortikotropin, follitropin, lutropin, melanotropin, prolaktin, somatotropin, thyrotropin, oksytocin og vasopressin, de frigivende hormoner og inhiberende fak-torene av hypothalamus, peptidhormonene fra pancreas, mage eller innvoll slik som glucagon, insulin, somatostatin, sekretin, gastrin og kolecystokinin, peptidhormoner av thyroid slik som kalcitonin, parathyrin og lignende.
Betegnelsen "vekstfaktor" betyr hormonlignende peptider og proteiner som støtter celledivisjon og celledifferensiering, promoterer vekst og organutvikling og er nød-vendig for skadeleging. Eksempler er kolonistimulerende faktorer, den epidermale vekstfaktor (EGF), erythropoietin, fibroblast vekstfaktorer, haematopoietiske vekstfaktorer, hepatocytt vekstfaktorer, insulin og insulinlignende vekstfaktorer, platelet avledet vekstfaktor (PDGF), trombopoietin, tranformerende vekstfaktorer, virale vekstfaktorer, men også interleukiner.
Betegnelsen "cytokiner" som anvendt her refererer til polypeptider som sekreres ved cellene og, etter binding med spesifikke reseptorer, kan påvirke funksjonen av andre, vanligvis tilstøtende celler. Cytokiner regulerer primært den komplekse in-teraksjon av cellene av immunsystemet. Eksempler på slike cytokiner er interferon-er, interleukiner, kjemokiner eller kolonistimulerende faktorer.
Betegnelsen "neurotransmitter" betyr messenger-substanser som forårsaker det kjemiske signal eller informasjonsoverføring på synapsene av nervesystemet. Av-hengig av deres kjemiske karakteristikker er neurotransmittere delt i aminosyrer slik som glutaminsyre, aminosyrederivater slik som acetylkolin, monoaminer som katakolaminer, slik som L-noradrenalin, L-adrenalin og dopamin, serotonin og peptider. Følgelig er "neuropeptidene" som bradykinin, men også enkephaliner, endor-fin etc. en undergruppe av neurotransmitterene.
Betegnelsen "koaguleringsfaktorer" som anvendt her betyr proteiner av koagula-sjonskaskade. Likeledes kan peptidet kobles til fumarsyren via en amidbinding være et antistoff-fragment, fragmentet omfatter fortrinnsvis også en gjen-kjenningsfrekvens og/eller bindingssekvens.
Fragmenter og/eller derivater av alle peptidene spesifisert over er egnet og kan også anvendes. Betegnelsen "fragment" betyr en del av de ovennevnte peptider som er i stand til amidbinding. Fortrinnsvis omfatter fragmentet gjenkjennings-sekvenser for å arrangere binding til en cellereseptor og/eller et aktivt senter for å overføre en aktiv funksjon.
Betegnelsen "derivat" betyr et peptid som kan avledes fra de ovennevnte peptider og/eller fragmenter ved homolog substitusjon, fjerning eller innsetting av en eller flere aminosyrer inn i eller fra peptidkjedene.
Fumarsyreamidene kan fremstilles i henhold til de ovennevnte US patenter til Blank.
I et andre aspekt vedrører den foreliggende oppfinnelsen et legemiddel omfattende et fumarsyreamid med den generelle formelen (I)
hvor
Ri representerer -OR3eller et D- eller L-aminosyreradikal -NH-CHR4-COOH
bundet via en amidbinding, hvor R3
er hydrogen, et rettkjedet eller forgrenet, valgfritt substituert Ci^alkylradikal, et fenylradikal eller C6-i0-aralkylradikal, og
R2representerer et D- eller L-aminosyreradikal -NH-CHR5-COOH bundet via en amidbinding,
hvor hver av R4og R5er uavhengig valgt fra gruppen bestående av sidekjedene av Ala, Val, Leu, Trp, Phe, Met, Tyr, Thr, Cys, Asn, Gin, Asp, Glu, Lys, Arg, His, Citrullin, Hcy, Hse, Hyp, Hyl, Orn, Sar og Me-Gly,
legemidlet er en fast oral doseringsform og har et enterisk belegg.
Legemidlet er nærmere angitt i uselvstendige krav 18-26.
Legemidlene oppnådd gjennom anvendelsen ifølge oppfinnelsen kan være til stede i former egnet for oral, nasal, parenteral, rektal, pulmonar, oftal eller transdermal administrasjon.
Fortrinnsvis er legemidlet ment for oral administrasjon. Den faste orale doseringsformen har et enterisk belegg (belegg resistent mot gastrisk syre) og kan være
valgt fra tabletter, belagte tabletter, o-kapsler, mikrokapsler, mikrotabletter, pelleter eller pulvere samt granulat, mikrotabletter, pelleter og pulverfylte kapsler, mikrotabletter fylt i kapsler og pulvere fylt i kapsler. Fortrinnsvis er den faste orale doseringsformen valgt fra tabletter, belagte tabletter, mikrotabletter, pelleter eller kapsler.
Prinsippmessig kan legemidlet av oppfinnelsen inneholde egnede farmasøytiske bærere, eksipienter, additiver etc. Disse er kjent for fagpersoner og er ikke nærmere forklart.
Anvendelsen av mikrotabletter eller pelleter er mest foretrukket. Fortrinnsvis har disse en gjennomsnittlig diameter på 300 til 5000 pm, mer foretrukket 300 til 2000 pm, når ubelagt.
Når administrert parenteralt ved injeksjon, er sammensetningen til stede i en form egnet for dette formål. Alle vanlige flytende bærere egnet for injeksjon kan anvendes.
I ethvert tilfelle er det foretrukket at legemidlet inneholder en mengde av fumarsyreamidet med formel (I) per enkel dose som tilsvarer 1 til 500 mg fumarsyre, fortrinnsvis 10 til 300 mg fumarsyre.
Claims (26)
1. Anvendelse av fumarsyreamider med den generelle formelen (I)
hvor
Ri representerer -OR3eller et D- eller L-aminosyreradikal -NH-CHR4-COOH bundet via en amidbinding, hvor R3
er hydrogen, et rettkjedet eller forgrenet, valgfritt substituert Ci.24alkylradikal, et fenylradikal eller C6-ioaralkylradikal, og
R2representerer et D- eller L-aminosyreradikal -NH-CHR5-COOH bundet via en amidbinding, hvor hver av R4og R5er uavhengig valgt fra gruppen bestående av sidekjedene av Ala, Val, Leu, Trp, Phe, Met, Tyr, Thr, Cys, Asn, Gin, Asp, Glu, Lys, Arg, His, Citrullin, Hcy, Hse, Hyp, Hyl, Orn, Sar og Me-Gly,
for å fremstille et legemiddel (1) for terapi av en autoimmun sykdom valgt fra gruppen bestående av polyartritt, multippel sklerose, transplantat-mot-vert reaksjoner, barneinntrådt diabetes, Hashimotos thyroiditis, Graves sykdom, systemisk Lupus erythematodes, Sjøgrens syndrom, pernisiøs anemi og kronisk aktiv (= lupoid) hepatitt; (2) for terapi eller anvendelse i transplantasjonsmedisin; (3) for terapi av mitokondriale sykdommer fra gruppen bestående av Parkinson syndrom, Alzheimers sykdom, Chorea Huntington sykdom, retinopathia pigmentosa eller former av mitokondrial encefalomyopati; eller (4) for terapi av en NF-kappaB mediert sykdom valgt fra gruppen bestående av progressiv systemisk skleroderma, osteokondritis syphilitica (Wegeners sykdom), cutis marmorata (livedo reticularis), Behcet sykdom, panarteritis,
colitis ulcerosa, vasculitis, osteoarthritis, urinsyregikt, arteriosklerose, Reiters sykdom, pulmonar granulomatosis, typer av encephalitis, endotoksisk sjokk (septisk-toksisk sjokk), sepsis, pneumoni, encephalomyelitis, anorexia nevrosa, hepatitt, Rennert T-lymphomatosis, mesanginal nephritis, post-angioplastisk restenosis, re-perfusions-syndrom, cytomegaloviral retinopati, adenovirale sykdommer, AIDS, Guillain-Barré syndrom, post-herpetisk eller post-zoster neuralgia, inflammatorisk demyeliniserende polyneuropati, mononeuropathia multiplex, mucoviscidosis, Bech-terews sykdom, Barett oesophagus, EBV (Epstein-Barr virus) infeksjon, hjertere-modelering, interstitial cystitis, diabetes mellitus type II, menneskelig tumor radio-sensitisasjon, multi-resistens av ondartede celler for kjemoterapeutiske midler, granuloma annulare og kreft.
2. Anvendelse ifølge krav 1, hvor Ri representerer -OR3og R2representerer et L-aminosyreradikal -NH-CHR5-COOH, hvor R5er valgt fra gruppen bestående av sidekjedene av Ala, Val, Leu, Trp, Phe, Met, Tyr, Thr, Cys, Asn, Gin, Asp, Glu, Lys, Arg, His, Citrullin, Hcy, Hse, Hyp, Hyl, Orn, Sar og Me-Gly.
3. Anvendelse ifølge krav 1, hvor Ri representerer -NH-CHR4-COOH og R2representerer -NH-CHR5-COOH, hvor R4og R5kan være samme eller forskjellig og er som definert i krav 1.
4. Anvendelse ifølge krav 1 eller 2, hvor R3er metyl eller etyl.
5. Anvendelse ifølge krav 1, 2 eller 3, hvor R5er valgt fra gruppen bestående av Gin, Asn, Lys, Arg og His.
6. Anvendelse ifølge ethvert av kravene 1-5, hvor legemidlet er i en form egnet for oral, nasal, parenteral, rektal, pulmonar, oftal eller transdermal administrasjon.
7. Anvendelse ifølge ethvert av kravene 1-5, hvor legemidlet er i en form egnet for oral administrasjon og er i formen av tabletter, belagte tabletter, kapsler, granulater, løsninger for å drikke, liposomer, nano-kapsler, mikrokapsler, mikrotabletter, pelleter eller pulvere; eller i formen av granulater, mikrotabletter, pelleter eller pulverfylte kapsler.
8. Anvendelse ifølge krav 7, hvor legemidlet er en fast oral doseringsform og har et enterisk belegg.
9. Anvendelse ifølge krav 7, hvor mi krota blettene eller pelletene uten belegg har en gjennomsnittlig diameter på 300 til 5000 pm.
10. Anvendelse ifølge krav 9, hvor den gjennomsnittlige diameter er 300 til 2000 pm.
11. Anvendelse ifølge ethvert av kravene 1-9, hvor legemidlet inneholder en mengde av fumarsyreamidet med formel (I) per enkel dose som tilsvarer 1 til 500 mg av fumarsyre.
12. Anvendelse ifølge krav 11, hvor legemidlet inneholder en mengde av fumarsyreamidet per enkel dose som tilsvarer 10 til 300 mg av fumarsyre.
13. Anvendelse ifølge ethvert av kravene 1-12, hvor hepatitt er valgt fra akutt hepatitt, kronisk hepatitt, toksisk hepatitt, alkohol-indusert hepatitt, viral hepatitt, gulsott, og lever insuffiens og cytomegalviral hepatitt.
14. Anvendelse ifølge ethvert av kravene 1-12, hvor adenoviral sykdom er valgt fra adenovirale forkjølelser, adenoviral pharyngoconjunctival feber og adenoviral ophthalmia.
15. Anvendelse ifølge ethvert av kravene 1-12, hvor kreft er valgt fra brystkreft, tarmkreft, melanoma, primær levercelle carcinoma, adenocarcinoma, Kaposis sar-coma, prostata carcinoma, leukemi, multippel myeloma (plasmocytoma), Burkitt lymphoma og Castleman tumor.
16. Anvendelse ifølge krav 15, hvor leukemi er akutt myeloid leukemi.
17. Legemiddel omfattende et fumarsyreamid med den generelle formelen (I)
hvor
Ri representerer -OR3eller et D- eller L-aminosyreradikal -NH-CHR4-COOH bundet via en amidbinding, hvor R3
er hydrogen, et rettkjedet eller forgrenet, valgfritt substituert Ci^alkylradikal, et fenylradikal eller C6-i0-aralkylradikal, og
R2representerer et D- eller L-aminosyreradikal -NH-CHR5-COOH bundet via en amidbinding,
hvor hver av R4og R5er uavhengig valgt fra gruppen bestående av sidekjedene av Ala, Val, Leu, Trp, Phe, Met, Tyr, Thr, Cys, Asn, Gin, Asp, Glu, Lys, Arg, His, Citrullin, Hcy, Hse, Hyp, Hyl, Orn, Sar og Me-Gly,
legemidlet er en fast oral doseringsform og har et enterisk belegg.
18. Legemiddel ifølge krav 17, hvor Ri representerer -OR3og R2representerer et L-aminosyreradikal -NH-CHR5-COOH, hvor R5er valgt fra gruppen bestående av sidekjedene av Ala, Val, Leu, Trp, Phe, Met, Tyr, Thr, Cys, Asn, Gin, Asp, Glu, Lys, Arg, His, Citrullin, Hcy, Hse, Hyp, Hyl, Orn, Sar og Me-Gly.
19. Legemiddel ifølge krav 17 eller 18, hvor R3er metyl eller etyl.
20. Legemiddel ifølge krav 17, hvor Ri representerer -NH-CHR4-COOH og R2representerer -NH-CHR5-COOH, hvor R4og R5kan være samme eller forskjellig og er som definert i krav 17.
21. Legemiddel ifølge krav 17, 18 eller 20, hvor R5er valgt fra gruppen bestående av Gin, Asn, Lys, Arg og His.
22. Legemiddel ifølge krav 17, hvor den faste orale doseringsformen er valgt fra tabletter, belagte tabletter, mikrotabletter, pelleter eller kapsler.
23. Legemiddel ifølge krav 22, hvor mikrotablettene eller pelletene uten belegg har en gjennomsnittlig diameter på 300 til 5000 pm.
24. Legemiddel ifølge krav 23, hvor den gjennomsnittlige diameter er 300 til 2000 pm.
25. Legemiddel ifølge ethvert av kravene 17-24, hvor legemidlet inneholder en mengde av fumarsyreamidet med formel (I) per enkel dose som tilsvarer 1 til 500 mg av fumarsyre.
26. Legemiddel ifølge krav 17-25, hvor legemidlet inneholder en mengde av fumarsyreamidet per enkel dose som tilsvarer 10 til 300 mg av fumarsyre.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10101307A DE10101307A1 (de) | 2001-01-12 | 2001-01-12 | Fumarsäurederivate als NF-kappaB-Inhibitor |
| DE10133004 | 2001-07-06 | ||
| PCT/EP2002/000107 WO2002055063A2 (de) | 2001-01-12 | 2002-01-08 | Fumarsäureamide |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20031748D0 NO20031748D0 (no) | 2003-04-15 |
| NO20031748L NO20031748L (no) | 2003-09-12 |
| NO333992B1 true NO333992B1 (no) | 2013-11-11 |
Family
ID=26008228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20031748A NO333992B1 (no) | 2001-01-12 | 2003-04-15 | Anvendelse av fumarsyreanhydrider og legemiddel omfattende et fumarsyreanhydrid |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US7157423B2 (no) |
| EP (1) | EP1372634B1 (no) |
| JP (1) | JP2004523511A (no) |
| AT (1) | ATE447945T1 (no) |
| AU (1) | AU2002219236B2 (no) |
| BG (1) | BG66256B1 (no) |
| CA (2) | CA2425599C (no) |
| CZ (1) | CZ304198B6 (no) |
| DE (1) | DE50213989D1 (no) |
| EE (1) | EE05472B1 (no) |
| HU (1) | HU230252B1 (no) |
| ME (1) | ME00135B (no) |
| NO (1) | NO333992B1 (no) |
| NZ (1) | NZ526100A (no) |
| PL (3) | PL392748A1 (no) |
| RS (1) | RS52083B (no) |
| RU (1) | RU2290946C2 (no) |
| SK (1) | SK288238B6 (no) |
| WO (1) | WO2002055063A2 (no) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| DE10217314A1 (de) * | 2002-04-18 | 2003-11-13 | Fumapharm Ag Muri | Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere |
| DE10360869A1 (de) * | 2003-09-09 | 2005-04-07 | Fumapharm Ag | Verwendung von Fumarsäurederivaten zur Therapie der Herzinsuffizienz, der Hyperkeratose und von Asthma |
| AU2004269903B2 (en) * | 2003-09-09 | 2010-09-02 | Biogen International Gmbh | The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma |
| US20140099364A2 (en) | 2004-10-08 | 2014-04-10 | Forward Pharma A/S | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
| DE102005022845A1 (de) * | 2005-05-18 | 2006-11-23 | Fumapharm Ag | Thiobernsteinsäurederivate und deren Verwendung |
| ATE455783T1 (de) * | 2005-07-07 | 2010-02-15 | Aditech Pharma Ag | Neue glucopyranoseester und glucofuranoseester von fumarsäurealkylestern und deren pharmazeutische verwendung |
| ATE554769T1 (de) * | 2006-12-06 | 2012-05-15 | Cornell Res Foundation Inc | Neuromuskuläre blocker mit mittlerer dauer und antagonisten advon |
| US20100130607A1 (en) * | 2007-02-08 | 2010-05-27 | Ralf Gold | Neuroprotection in demyelinating diseases |
| ES2916649T3 (es) | 2007-02-08 | 2022-09-21 | Biogen Ma Inc | Composiciones y usos para el tratamiento de la esclerosis múltiple |
| EP2650279A3 (en) | 2008-08-19 | 2014-02-12 | XenoPort, Inc. | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
| PT2379063E (pt) | 2009-01-09 | 2013-05-03 | Forward Pharma As | Formulação farmacêutica compreendendo um ou mais ésteres de ácido fumárico numa matriz de erosão |
| WO2010107488A1 (en) | 2009-03-17 | 2010-09-23 | Cornell University | Reversible nondepolarizing neuromuscular blockade agents and methods for their use |
| WO2011022491A1 (en) | 2009-08-19 | 2011-02-24 | Cornell University | Cysteine for physiological injection |
| CN103649041A (zh) | 2011-06-08 | 2014-03-19 | 比奥根艾迪克Ma公司 | 制备高纯度和结晶的富马酸二甲酯的方法 |
| US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| US8952006B2 (en) | 2012-02-07 | 2015-02-10 | Xenoport, Inc. | Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use |
| JP2015518854A (ja) * | 2012-05-23 | 2015-07-06 | セリックスビオ プライヴェート リミテッド | 多発性硬化症の治療のための組成物および方法 |
| WO2014031844A1 (en) | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
| AU2013305684B2 (en) | 2012-08-22 | 2016-11-24 | Xenoport, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
| JP6506174B2 (ja) | 2012-12-21 | 2019-04-24 | バイオジェン エムエー インコーポレイテッド | 重水素置換されたフマル酸誘導体 |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| RS57497B1 (sr) | 2013-03-14 | 2018-10-31 | Alkermes Pharma Ireland Ltd | Prolekovi fumarata i njihova upotreba u lečenju raznih bolesti |
| US10179118B2 (en) | 2013-03-24 | 2019-01-15 | Arbor Pharmaceuticals, Llc | Pharmaceutical compositions of dimethyl fumarate |
| WO2014197860A1 (en) | 2013-06-07 | 2014-12-11 | Xenoport, Inc. | Method of making monomethyl fumarate |
| US9421182B2 (en) | 2013-06-21 | 2016-08-23 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| WO2015017762A1 (en) * | 2013-08-01 | 2015-02-05 | Xenoport, Inc. | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
| TW201516020A (zh) | 2013-09-06 | 2015-05-01 | Xenoport Inc | （ｎ，ｎ－二乙基胺甲醯基）甲基（２ｅ）丁－２－烯－１，４－二酸甲酯之晶形、合成方法及用途 |
| EP3110793B1 (en) | 2014-02-24 | 2019-08-21 | Alkermes Pharma Ireland Limited | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases |
| US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
| EP3501510B1 (en) | 2014-02-28 | 2020-07-01 | Banner Life Sciences LLC | Controlled release enteric soft capsules of fumarate esters |
| US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
| US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
| WO2016061393A1 (en) | 2014-10-15 | 2016-04-21 | Xenoport, Inc. | Fumarate compounds, pharmaceutical compositions, and methods of use |
| WO2016074684A1 (en) | 2014-11-11 | 2016-05-19 | Syddansk Universitet | Fumaric acid derivatives for medical use |
| EA037666B1 (ru) | 2015-02-08 | 2021-04-28 | Алкермес Фарма Айрленд Лимитед | Фармацевтическая композиция, содержащая 2-(2,5-диоксопирролидин-1-ил)этилметилфумарат, и ее применение в медицине |
| US9636321B2 (en) | 2015-03-27 | 2017-05-02 | Symbionyx Pharmaceuticals Inc. | Compositions and methods for treating psoriasis |
| WO2017060400A1 (en) | 2015-10-07 | 2017-04-13 | Neurovive Pharmaceutical Ab | Protected carboxylic acid-based metabolites for the treatment of disesases related to mitochondrial dysfunctions |
| WO2017147505A1 (en) * | 2016-02-26 | 2017-08-31 | The Regents Of The University Of California | Methods of treating muscle and liver disorders |
| WO2020094767A1 (en) | 2018-11-08 | 2020-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of nrf2 activators for the treatment of staphylococcus aureus infections |
| WO2021142062A1 (en) | 2020-01-10 | 2021-07-15 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
| WO2024047248A1 (en) | 2022-09-02 | 2024-03-07 | Institut National de la Santé et de la Recherche Médicale | Use of nrf2 activators for the treatment of cerebral small vessel disease |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2993837A (en) * | 1959-07-13 | 1961-07-25 | Frosst & Co Charles E | Enteric coated tablets |
| DE1618162B1 (de) | 1967-05-20 | 1971-05-19 | Basf Ag | Verfahren zur Herstellung con Cyclohexan-1.2.3.4.5.6-hexan-carbonsäure |
| US3832287A (en) * | 1972-03-02 | 1974-08-27 | Lilly Co Eli | Dipeptide antibiotic and method for the production thereof |
| DE2212369A1 (de) | 1972-03-15 | 1973-09-20 | Basf Ag | Cyclohexanhexacarbonsaeure |
| DE2530372A1 (de) | 1975-07-08 | 1977-01-13 | Walter Dr Schweckendiek | Pharmazeutische zubereitungen zur behandlung von psoriasis |
| DE2621214C3 (de) | 1976-05-13 | 1981-11-12 | Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen | Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen |
| DE3127432A1 (de) | 1981-07-11 | 1983-02-03 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von fumarsaeuremonoester |
| DE3233830A1 (de) * | 1982-09-11 | 1984-03-15 | Hoechst Ag, 6230 Frankfurt | Perfluoralkyl-malein- und -fumarsaeureamide, verfahren zu deren herstellung und ihre verwendung als schmutzabweisendes mittel |
| PL144744B1 (en) * | 1984-10-16 | 1988-06-30 | Politechnika Gdanska | Method of obtaining novel derivatives of l-2,3-diaminopropanic acid exhibiting dipeptide structure |
| US5149695A (en) | 1985-01-15 | 1992-09-22 | Speiser Peter P | Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same |
| CH664150A5 (de) | 1985-01-15 | 1988-02-15 | Peter Paul Prof Dr Speiser | Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen. |
| JPS61194020A (ja) | 1985-02-22 | 1986-08-28 | Dai Ichi Seiyaku Co Ltd | 網膜症治療剤 |
| IL83775A (en) * | 1987-09-04 | 1991-12-15 | Dexter Chemical Corp | Amino acid esters and amides of fumaric acid and pharmaceutical compositions containing them for use in the treatment of psoriasis |
| US5242905A (en) * | 1987-09-04 | 1993-09-07 | Dexter Chemical Corporation | Pharmaceutical compositions for the treatment of psoriasis |
| US5214196A (en) * | 1987-09-04 | 1993-05-25 | Dexter Chemical Corporation | Diethyl ester of di-glycyl fumaramide |
| US5424332A (en) | 1987-10-19 | 1995-06-13 | Speiser; Peter P. | Pharmaceutical composition and process for the production thereof |
| US4959389A (en) | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
| US5350741A (en) * | 1988-07-30 | 1994-09-27 | Kanji Takada | Enteric formulations of physiologically active peptides and proteins |
| DE3834794A1 (de) | 1988-10-12 | 1990-04-19 | F Schielein | Oral zu verabreichendes mittel zur behandlung von psoriasis |
| AU1271592A (en) | 1991-01-18 | 1992-08-27 | Dexter Chemical Corporation | Malic acid derivatives and compositions for the treatment of psoriasis |
| DE4103649A1 (de) * | 1991-02-07 | 1992-08-13 | Basf Ag | Neue antikoagulatorisch wirksame peptide |
| IT1251166B (it) | 1991-08-09 | 1995-05-04 | Chiesi Farma Spa | Derivati di geneserina,loro preparazione e composizioni farmaceutiche che li contengono |
| US5763408A (en) * | 1992-06-03 | 1998-06-09 | Fuji Photo Film Co., Ltd. | Amino acid derivatives and application thereof |
| DE4494231T1 (de) | 1993-06-08 | 1996-10-17 | Raymond K Brown | Therapeutische Zusammensetzung und ihre Anwendung |
| US5407772A (en) | 1993-11-30 | 1995-04-18 | Xerox Corporation | Unsaturated polyesters |
| DK0750616T3 (da) | 1994-03-16 | 2001-07-23 | Cenes Ltd | Syreadditionssalte af 2,3,4,5-tetrahydro-1H-3-benzazapinforbindelser |
| US5569742A (en) * | 1994-06-22 | 1996-10-29 | The Salk Institute For Biological Studies | Centrally truncated NPY cyclic peptides |
| IL110380A0 (en) | 1994-07-20 | 1994-10-21 | Agis Ind 1983 Ltd | Antiviral topical pharmaceutical compositions |
| US5589504A (en) | 1994-07-26 | 1996-12-31 | Cornell Research Foundation, Inc. | Treatment of newborn jaundice |
| US6011000A (en) | 1995-03-03 | 2000-01-04 | Perrine; Susan P. | Compositions for the treatment of blood disorders |
| US6047575A (en) * | 1995-05-19 | 2000-04-11 | Slc Technologies, Inc. | Electronic padlock |
| US6046180A (en) * | 1996-06-17 | 2000-04-04 | Guilford Pharmaceuticals Inc. | NAALADase inhibitors |
| JP2001527517A (ja) | 1996-07-26 | 2001-12-25 | スーザン・ピー・ペリーネ | 血液、ウイルス性および細胞性疾患の治療組成物 |
| WO1998027970A2 (en) | 1996-12-24 | 1998-07-02 | National Research Council Of Canada | Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals |
| US5972363A (en) | 1997-04-11 | 1999-10-26 | Rohm And Haas Company | Use of an encapsulated bioactive composition |
| DE19721099C2 (de) * | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
| JP2001521002A (ja) | 1997-10-24 | 2001-11-06 | コーネル リサーチ ファンデーション インク． | 脳の代謝機能不全のための栄養補充剤 |
| DE19814358C2 (de) | 1998-03-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn |
| DE19839566C2 (de) | 1998-08-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten in der Transplantationsmedizin |
| DE19848260C2 (de) | 1998-10-20 | 2002-01-17 | Fumapharm Ag Muri | Fumarsäure-Mikrotabletten |
| DE19853487A1 (de) * | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| DE10000577A1 (de) | 2000-01-10 | 2001-07-26 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten |
| AU2004269903B2 (en) | 2003-09-09 | 2010-09-02 | Biogen International Gmbh | The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma |
-
2002
- 2002-01-08 WO PCT/EP2002/000107 patent/WO2002055063A2/de active IP Right Grant
- 2002-01-08 DE DE50213989T patent/DE50213989D1/de not_active Expired - Lifetime
- 2002-01-08 HU HU0302656A patent/HU230252B1/hu not_active IP Right Cessation
- 2002-01-08 EP EP02729423A patent/EP1372634B1/de not_active Expired - Lifetime
- 2002-01-08 JP JP2002555797A patent/JP2004523511A/ja active Pending
- 2002-01-08 EE EEP200300280A patent/EE05472B1/xx not_active IP Right Cessation
- 2002-01-08 SK SK827-2003A patent/SK288238B6/sk not_active IP Right Cessation
- 2002-01-08 CZ CZ2003-1919A patent/CZ304198B6/cs not_active IP Right Cessation
- 2002-01-08 CA CA2425599A patent/CA2425599C/en not_active Expired - Fee Related
- 2002-01-08 CA CA2776023A patent/CA2776023A1/en not_active Abandoned
- 2002-01-08 RS YU56003A patent/RS52083B/sr unknown
- 2002-01-08 PL PL392748A patent/PL392748A1/pl not_active Application Discontinuation
- 2002-01-08 PL PL02364222A patent/PL364222A1/xx not_active IP Right Cessation
- 2002-01-08 RU RU2003124752/15A patent/RU2290946C2/ru not_active IP Right Cessation
- 2002-01-08 AU AU2002219236A patent/AU2002219236B2/en not_active Ceased
- 2002-01-08 PL PL392750A patent/PL392750A1/pl not_active Application Discontinuation
- 2002-01-08 AT AT02729423T patent/ATE447945T1/de not_active IP Right Cessation
- 2002-01-08 ME MEP-2008-206A patent/ME00135B/me unknown
- 2002-01-08 US US10/433,295 patent/US7157423B2/en not_active Expired - Lifetime
- 2002-01-08 NZ NZ526100A patent/NZ526100A/en not_active IP Right Cessation
-
2003
- 2003-04-15 NO NO20031748A patent/NO333992B1/no not_active IP Right Cessation
- 2003-05-09 BG BG107795A patent/BG66256B1/bg unknown
-
2006
- 2006-05-31 US US11/421,083 patent/US7432240B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO333992B1 (no) | Anvendelse av fumarsyreanhydrider og legemiddel omfattende et fumarsyreanhydrid | |
| US8067467B2 (en) | Thiosuccinic acid derivatives and the use thereof | |
| US6436992B1 (en) | Use of fumaric acid derivatives | |
| RU2282440C2 (ru) | ПРОИЗВОДНЫЕ ФУМАРОВОЙ КИСЛОТЫ В КАЧЕСТВЕ ИНГИБИТОРА NF-kappaB | |
| US8980832B2 (en) | Use of fumaric acid derivatives for treating cardiac insufficiency, and asthma | |
| RU2459621C2 (ru) | Применение производных фумаровой кислоты для лечения сердечной недостаточности, инфаркта миокарда и стенокардии | |
| US6011010A (en) | Cytotoxic and antiviral compound | |
| DE3243370A1 (de) | Benzoylthioverbindungen, ihre herstellung und verwendung als arzneimittel | |
| AU677258B2 (en) | Cytotoxic and antiviral compound | |
| EP0322633B1 (en) | Mercapto-acylamino acid antihypertensives | |
| EP0090798A1 (en) | A drug based on a substance p antagonist | |
| US20090318330A1 (en) | Combination of amino acid solution and a gelatin derivative for inhibiting renal up-take | |
| EP0351017B1 (en) | Pharmaceutical composition useful for the treatment of cardiovascular diseases | |
| JPH0193526A (ja) | 白血球減少の回復剤 | |
| JPH0193523A (ja) | 白血球減少の回復剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |